MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/1753-0407.12928

Медицинская библиотека · Journal of diabetes · 2019

Effect of basal insulin supplement therapy on diabetic retinopathy in short-duration type 2 diabetes: A one-year randomized parallel-group trial.

Mu Pan-Wei, Tang Xi-Xiang, Tan Ying, Wang Yi-Na, Lin Shuo, Wang Man-Man, Shu Jiong, Wang Jing, Zhang Yong-Jun, Liang Hua, Lin Bai-Run, Cai Meng-Yin, Chen Yan-Ming

СтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

BACKGROUND

In this study, we compared the effect on diabetic retinopathy (DR) between oral antidiabetic drugs (OADs) alone and in combination with basal insulin-supported OADs therapy (BOT). [Correction added on 11 November 2019, after first online publication: In Abstract under Background section, "DR" has been corrected into "diabetic retinopathy (DR)".]

METHODS

Between January 2015 and January 2018, this study enrolled 290 patients (age 18-65 years) with diabetes duration between 0 and 5 years. Patients were randomly assigned to receive OADs or BOT after 14 days intensive insulin treatment. Examinations were performed at the beginning and end of the study.

RESULTS

Fewer patients developed DR in the BOT than OADs group (8 [6.06%] vs 12 [8.3%], respectively), and all cases of DR were non-proliferative. Blood glucose concentrations were higher in the BOT than OADs group at the 3rd month, but lower in the former at the 6th and 12th month. The rate of reaching target HbA1c ≤7% was lower in the BOT than OADs group at the 3rd month (63.6% vs 72.2%, respectively), similar between the two groups at the 6th month (60.6% vs 66.6%, respectively) and higher in the BOT group at the 12th month (75.0% vs 61.1%, respectively). The SD of fasting blood glucose (FBG), coefficient of variation of FBG, SD of blood glucose (SDBG), and mean amplitude of glycemic excursions were lower in the BOT than OADs group. Changes in the levels of three cytokines (interleukin [IL]-1β, IL-6, and IL-17α) were significantly less in the BOT than OADs group.

CONCLUSIONS

Twelve months of BOT decreased the incidence of DR in short-duration type 2 diabetes by reducing glycemia more effectively, stably, and completely than OADs alone.

Для цитирования: Mu Pan-Wei, Tang Xi-Xiang, Tan Ying, Wang Yi-Na, Lin Shuo, Wang Man-Man, Shu Jiong, Wang Jing, Zhang Yong-Jun, Liang Hua, Lin Bai-Run, Cai Meng-Yin, Chen Yan-Ming. Effect of basal insulin supplement therapy on diabetic retinopathy in short-duration type 2 diabetes: A one-year randomized parallel-group trial.. Journal of diabetes. 2019. DOI: 10.1111/1753-0407.12928.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.